# OnCo record nct04165070 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct04165070/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct04165070", "NCT04165070" ;
  schema:name "KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)"@en ;
  schema:alternateName "KEYMAKER-U01"@en ;
  schema:description "A phase 1/2 trial of Pembrolizumab, Carboplatin, Pemetrexed and Ifinatamab deruxtecan in non-small-cell lung cancer, run by Merck Sharp & Dohme LLC, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct04165070/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT04165070> ;
  onco:status "recruiting" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "1/2" ;
  schema:startDate "2019-12-19" ;
  onco:cancers <https://onco.cc/cancers/nsclc/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/pemetrexed/>, <https://onco.cc/drugs/ifinatamab-deruxtecan/>, <https://onco.cc/drugs/vibostolimab/>, <https://onco.cc/drugs/boserolimab/> ;
  onco:companies <https://onco.cc/companies/merck/>, <https://onco.cc/companies/daiichi-sankyo/> .